These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 10683014)

  • 21. [Fusion inhibitors. One year therapy with T-20--initial evaluation].
    Goebel FD
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():42-3. PubMed ID: 15373046
    [No Abstract]   [Full Text] [Related]  

  • 22. Factors associated with incomplete virological response to highly active antiretroviral therapy.
    Welch K; Morse A; Clark R; Ogbuokiri T
    Clin Infect Dis; 2000 Feb; 30(2):407-8. PubMed ID: 10671360
    [No Abstract]   [Full Text] [Related]  

  • 23. Rilpivirine: a step forward in tailored HIV treatment.
    Schrijvers R; Desimmie BA; Debyser Z
    Lancet; 2011 Jul; 378(9787):201-3. PubMed ID: 21763920
    [No Abstract]   [Full Text] [Related]  

  • 24. Status of anti-HIV-1 chemotherapy in Japan.
    Oishi T; Sugiura W; Matsuda M; Abumi H; Okano A; Yamada K; Koike M; Taki M; Ishikawa M; Miura T; Fukutake K; Gouchi K; Ajisawa A; Iwamoto A; Hanabusa H; Mimaya J; Takamatsu J; Takata N; Kakishita E; Higasa S; Yoshioka A; Kashiwagi S; Shirahata A; Nagai Y
    Jpn J Infect Dis; 1999 Apr; 52(2):51-2. PubMed ID: 10817968
    [No Abstract]   [Full Text] [Related]  

  • 25. Transmission of drug-resistant strains of HIV-1: unfortunate, but inevitable.
    Cohen OJ; Fauci AS
    Lancet; 1999 Aug; 354(9180):697-8. PubMed ID: 10475176
    [No Abstract]   [Full Text] [Related]  

  • 26. [Antiretroviral therapy in 2004].
    Jablonowski H
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():46-8, 50-1. PubMed ID: 15373049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [First line therapy. Tenofovir DF/emtricitabine--the potent backbone].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():12-4. PubMed ID: 19024908
    [No Abstract]   [Full Text] [Related]  

  • 28. [Valuable combination partner. Great benefit for therapy naive patients].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():82-4. PubMed ID: 15373061
    [No Abstract]   [Full Text] [Related]  

  • 29. [Tenofovir in Study 903. Also effective and tolerable in first-line therapy].
    MMW Fortschr Med; 2002 Aug; 144(33-34):61. PubMed ID: 12380158
    [No Abstract]   [Full Text] [Related]  

  • 30. [First nucleotide analog against HIV. Lowers viral load also in drug resistance].
    MMW Fortschr Med; 2002 Aug; 144(33-34):60-1. PubMed ID: 12380157
    [No Abstract]   [Full Text] [Related]  

  • 31. Viral load and transmission.
    AIDS Patient Care STDS; 2000 Apr; 14(4):227. PubMed ID: 10806649
    [No Abstract]   [Full Text] [Related]  

  • 32. Immunovirological outcomes and resistance patterns at 4 years of antiretroviral therapy use in HIV-infected patients in Cambodia.
    Pujades-Rodríguez M; Schramm B; Som L; Nerrienet E; Narom P; Chanchhaya N; Ferradini L; Balkan S
    Trop Med Int Health; 2011 Feb; 16(2):205-13. PubMed ID: 21087376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maraviroc reduces viral load in naive patients at 48 weeks.
    AIDS Patient Care STDS; 2007 Sep; 21(9):703-4. PubMed ID: 17941136
    [No Abstract]   [Full Text] [Related]  

  • 34. [Antiretroviral therapy in patients infected with HIV-1].
    Corti ME
    Medicina (B Aires); 1998; 58 Suppl 1():49-56. PubMed ID: 9674248
    [No Abstract]   [Full Text] [Related]  

  • 35. Residual HIV-1 disease in the era of highly active antiretroviral therapy.
    Pomerantz RJ
    N Engl J Med; 1999 May; 340(21):1672-4. PubMed ID: 10341281
    [No Abstract]   [Full Text] [Related]  

  • 36. Potential new therapies for the treatment of HIV-1 infection.
    Condra JH; Miller MD; Hazuda DJ; Emini EA
    Annu Rev Med; 2002; 53():541-55. PubMed ID: 11818489
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abacavir for salvage or intensification.
    Torres G
    GMHC Treat Issues; 1999 Jan; 13(1):4-5. PubMed ID: 11366111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elvucitabine data released at CROI.
    AIDS Patient Care STDS; 2010 Mar; 24(3):198. PubMed ID: 20235383
    [No Abstract]   [Full Text] [Related]  

  • 39. [Therapeutic effect and safety evaluation on 6-year highly active antiretroviral therapy for Chinese HIV-1 infected patients].
    Zhou H; Zheng Y; He Y; Gong G; Chen Z; Liu M; Yin W; Liu C
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Aug; 34(8):731-7. PubMed ID: 19734579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.
    Fätkenheuer G; Pozniak AL; Johnson MA; Plettenberg A; Staszewski S; Hoepelman AI; Saag MS; Goebel FD; Rockstroh JK; Dezube BJ; Jenkins TM; Medhurst C; Sullivan JF; Ridgway C; Abel S; James IT; Youle M; van der Ryst E
    Nat Med; 2005 Nov; 11(11):1170-2. PubMed ID: 16205738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.